Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study


1Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA; 2Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland; 3Department of Clinical Oncology, State Key Laboratory of South China, Chinese University of Hong Kong, Shatin, Hong Kong; 4Department of Medicine, Massachusetts General Hospital, Boston, USA; 5Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; 6Irvine School of Medicine, Chao Family Comprehensive Cancer Center, University of California, Orange, USA; 7Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France; 8Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland; 9Department of Oncology, University of Turin, Turin, Italy; 10Catalan Institute of Oncology, Barcelona, Spain; 11F. Hoffmann-La Roche Ltd, Basel, Switzerland; 12Division of Medical Oncology, University of Colorado, Aurora, USA

*Correspondence to: Prof. Shirish Gadgeel, Department of Internal Medicine, Division of Hematology & Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. Tel: +1 7346476883; E-mail: sgadgeel@med.umich.edu

†Affiliation correct at time of study conduct.

Background: The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with alectinib versus crizotinib. Here, we present detailed central nervous system (CNS) efficacy data from ALEX.

Patients and methods: Overall, 303 patients aged ≥18 years underwent 1:1 randomization to receive twice-daily doses of alectinib 600 mg or crizotinib 250 mg. Brain imaging was conducted in all patients at baseline and every subsequent 8 weeks. End points (analyzed by subgroup: patients with/without baseline CNS metastases; patients with/without prior radiotherapy) included PFS, CNS objective response rate (ORR), and time to CNS progression.

Results: In total, 122 patients had Independent Review Committee-assessed baseline CNS metastases (alectinib, n = 64; crizotinib, n = 58), 43 had measurable lesions (alectinib, n = 21; crizotinib, n = 22), and 46 had received prior radiotherapy (alectinib, n = 25; crizotinib, n = 21). Investigator-assessed PFS with alectinib was consistent between patients with baseline CNS metastases [hazard ratio (HR) 0.40, 95% confidence interval (CI): 0.25–0.64] and those without (HR 0.51, 95% CI: 0.33–0.80, Pinteraction = 0.36). Similar results were seen in patients regardless of prior radiotherapy. Time to CNS progression was significantly longer with alectinib versus crizotinib and comparable between patients with and without baseline CNS metastases (P < 0.0001). CNS ORR was 85.7% with alectinib versus 71.4% with crizotinib in patients who received prior radiotherapy and 78.6% versus 40.0%, respectively, in those who had not.

Conclusion: Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib in patients with previously untreated, advanced ALK+ NSCLC, irrespective of prior CNS disease or radiotherapy.

Clinical trial registration: ClinicalTrials.gov NCT02075840

Key words: alectinib, ALK-positive, CNS, NSCLC

Introduction

Anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) is characterized by a high prevalence of central nervous system (CNS) involvement [1] and brain metastases [2, 3]. Previously, crizotinib was the standard of care (SOC) first-line treatment of ALK+ NSCLC [4]. Most crizotinib-treated patients relapse within 1 year because of poor CNS
penetration [5] or development of resistance mutations [6]. In the phase III PROFILE 1014 study, although intracranial disease control rate was significantly higher with crizotinib than with chemotherapy, there was no significant difference in intracranial time to tumor progression between the treatments [7].

Alectinib is a highly selective ALK inhibitor with proven CNS efficacy [8–13]. Unlike crizotinib, alectinib demonstrates effective CNS penetration and is not a substrate for P-glycoprotein, which promotes efflux at the blood–brain barrier [11]. The phase III ALEX trial (BO28984, NCT02075840) compared alectinib with crizotinib as the first-line treatment for ALK+ advanced NSCLC. Patients with/without asymptomatic CNS metastases, including treated/untreated CNS disease, were permitted. In the primary analysis, the primary end point [investigator-assessed progression-free survival (PFS)] was significantly improved with alectinib versus crizotinib: hazard ratio (HR) 0.47 [95% confidence interval (CI): 0.34–0.65; P < 0.001], median PFS for alectinib not reached (NR) [13]. With 10 months’ longer follow-up, median PFS was 34.8 months (95% CI: 17.7–not estimable) with alectinib and 10.9 months (95% CI: 9.1–12.9) with crizotinib (HR 0.43, 95% CI: 0.32–0.58) [14]. Based on ALEX, alectinib was approved for the first-line treatment of ALK+ NSCLC.

ALEX was designed to capture CNS progression by prospectively monitoring patients with uniform brain imaging. At the primary data analysis, 18 patients (12%) receiving alectinib had CNS progression as the first progression event versus 68 patients (45%) receiving crizotinib [cause-specific HR (csHR) 0.16; 95% CI: 0.10–0.28; P < 0.001] [13]. Here, we report further CNS efficacy results from ALEX.

Methods

Study design

Full methodology has been published [13]. Patients with stage III/IV ALK+ NSCLC (by central immunohistochemistry testing) were randomized 1:1 to receive alectinib 600 mg or crizotinib 250 mg twice-daily until disease progression, toxicity, withdrawal, or death. Randomization was stratified by performance status, race, and CNS metastases status. Patients with treated/untreated asymptomatic brain metastases were eligible; previous CNS radiotherapy was allowed if completed ≥14 days before enrolment. Crossover was not permitted.

ALEX was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients.

End points

CNS efficacy end points [PFS, time to CNS progression, CNS objective response rate (ORR), and CNS duration of response (DoR)] were analyzed by subgroup: patients with/without baseline CNS disease and patients with baseline CNS disease with/without prior radiotherapy.

Assessments

Computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, and brain were carried out at screening. Subsequent tumor assessment, including systematic brain imaging, was carried out every 8 weeks until progression, and at the post-treatment visit (4 weeks after treatment discontinuation). Scans were repeated for suspected progression.

CNS end points were assessed by an Independent Review Committee (IRC). Baseline CNS metastases with a minimum size of 10 mm (CT/MRI scan), 10 mm caliper measurement (clinical examination), or 20 mm (chest X-ray) were considered measurable. Response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exploratory CNS end points (ORR, DoR, and time to CNS progression) were assessed by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria in patients with baseline CNS metastases.

Statistical analysis

Comparisons of PFS between treatment groups were based on a two-sided log-rank test. Kaplan–Meier methods were used to estimate median PFS with 95% CIs. HRs with 95% CIs were estimated using Cox proportional-hazards regression. CNS end points assessed by RANO-BM were analyzed using the same methods as those assessed by RECIST [13].

Time to CNS progression was analyzed using competing risk methodology with minor statistical differences for the cumulative incidence rates (CIR) of CNS progression and time to CNS progression analysis. These analyses consider the possibility that at the time of analysis, a patient may have CNS progression (with/without systemic progression), non-CNS progression, or death, and include only the first event (see supplementary Appendix, available at Annals of Oncology online).

Results

Patients

At data cutoff (9 February 2017), 303 patients (alectinib, n = 152; crizotinib, n = 151) were randomized; baseline characteristics of the intent-to-treat (ITT) population have been reported [13]. Forty percent of patients had IRC-assessed baseline CNS metastases (n = 122, measurable and/or non-measurable; n = 43, measurable [Figure 1]). Baseline characteristics were generally balanced between arms (Table 1). A higher proportion of past and current smokers received alectinib versus crizotinib (36% and 11% versus 24% and 2%, respectively). Among patients with measurable and/or non-measurable baseline CNS metastases, 46 had received prior radiotherapy. Patients who received treatment for CNS progression after study start are described in supplementary Table S1, available at Annals of Oncology online). The median number of measurable/non-measurable baseline CNS lesions per patient was two in both treatment arms (alectinib, range: 1–10; crizotinib, range: 1–6).

PFS

Investigator-assessed PFS was significantly prolonged with alectinib versus crizotinib in patients with (HR 0.40, 95% CI: 0.25–0.64) and without baseline CNS metastases (HR 0.51, 95% CI: 0.33–0.80; Figure 2). There was no discernable difference in the effect of alectinib between patients with/without baseline CNS metastases (interaction P = 0.36). PFS was significantly longer with alectinib versus crizotinib in patients with (HR 0.34, 95% CI: 0.15–0.78) and without prior radiotherapy (HR 0.44, 95% CI: 0.25–0.78; Figure 2).
Time to CNS progression

Time to CNS progression, without prior non-CNS progression, was significantly longer with alectinib versus crizotinib, and comparable between patients with \[ \text{csHR 0.18 (95\% CI: 0.09–0.36)} \] and without baseline CNS metastases \[ \text{csHR 0.14 (95\% CI: 0.06–0.33); Table 2} \] or with \[ \text{csHR 0.11 (95\% CI: 0.03–0.42)} \] or without prior radiotherapy \[ \text{csHR 0.22 (95\% CI: 0.10–0.50); supplementary Table S2, available at Annals of Oncology online}. \]

The CIR of CNS progression, without prior non-CNS progression, was lower over time with alectinib versus crizotinib regardless of baseline CNS metastases or prior radiotherapy (Figure 3). Twelve-month CIR for CNS progression (without prior non-CNS progression) were: 58.3\% (95\% CI: 43.4–70.5) crizotinib and 16.0\% (95\% CI: 8.2–26.2) alectinib in patients with baseline CNS metastases; and 31.5\% (95\% CI: 22.1–41.3) crizotinib and 4.6\% (95\% CI: 1.5–10.6) alectinib in patients without (Figure 3 and supplementary Table S3, available at Annals of Oncology online). At primary analysis, 18 alectinib and 68 crizotinib patients had CNS progression without prior non-CNS progression; of these, 6 and 8, respectively, had systemic progression at the time of CNS progression. CIR for death (without prior progression) for the subgroups are shown in supplementary Figure S1 and Table S3, available at Annals of Oncology online. Similar differences between 12-month CIRs for CNS or non-CNS progression as the first site of progression between alectinib and crizotinib were seen in patients with/without prior radiotherapy.

Forty crizotinib-treated patients experienced an isolated asymptomatic CNS progression per investigator, regardless of baseline CNS metastases, versus 5 alectinib-treated patients. Of those, 30/40 patients (75\%, crizotinib), and 5/5 patients (100\%, alectinib) received allocated to study treatment after...
asymptomatic CNS progression. Continuation of study treatment after symptomatic CNS progression was not permitted.

**CNS response (RECIST)**

CNS ORR in patients with measurable baseline CNS metastases was 85.7% \((n = 6/7)\) alectinib versus 71.4% \((n = 5/7)\) crizotinib in patients with prior radiotherapy, and 78.6% \((n = 11/14)\) alectinib versus 40.0% \((n = 6/15)\) crizotinib in patients without (Figure 4). In patients with measurable/non-measurable baseline CNS metastases, CNS ORR was 36.0% \((n = 9/25)\) alectinib versus 28.6% \((n = 6/21)\) crizotinib without prior radiotherapy (Figure 4). Complete response (CR) rates were higher for alectinib versus crizotinib in patients with measurable/non-measurable baseline CNS metastases with prior radiotherapy (61.5% versus 10.8%) and without (20.0% versus 4.8%; Figure 4).

CNS DoR in patients with measurable/non-measurable baseline CNS metastases was longer for alectinib versus crizotinib in patients with prior radiotherapy \([\text{median NR (95% CI: 14.8–NR) versus 11.1 months (95% CI: 13.7–18.1)}];\) Figure 4C) and without \([\text{median NR (95% CI: 13.4–NR) versus 3.7 months (95% CI: 2.3–5.5)}];\) Figure 4D). Data were similar for patients with measurable baseline CNS metastases.

### Efficacy by RANO-BM criteria

Data assessed by RANO-BM criteria were consistent with RECIST-assessed findings \(\text{(supplementary Table S4, available at Annals of Oncology online)}\). In 32 patients with measurable baseline CNS metastases \((\text{alectinib, } n = 15; \text{crizotinib, } n = 17)\), 33% \((n = 5)\) achieved a CNS CR with alectinib versus 0% with crizotinib; 20% \((n = 3)\) achieved a partial response with alectinib versus 29.4% \((n = 5)\) with crizotinib although the sample size was small \(\text{(supplementary Table S5, available at Annals of Oncology online)}\). Median CNS DoR in patients with baseline measurable CNS metastases was 17.3 months with crizotinib and NR with alectinib. CNS ORR according to prior radiotherapy treatment is shown in supplementary Table S5, available at Annals of Oncology online.

Time to CNS progression was significantly longer with alectinib versus crizotinib in patients with baseline measurable/non-measurable CNS metastases \((\text{csHR 0.23; 95% CI: 0.12–0.48; supplementary Table S6, available at Annals of Oncology online)}\). CIR of CNS progression in patients with measurable/non-measurable baseline CNS metastases \(\text{(supplementary Figure S2, available at Annals of Oncology online)}\) were consistently lower over time with alectinib versus crizotinib. Twelve-month CIRs of CNS progression \(\text{(without prior non-CNS progression)}\) were 59.4% \((95\% \text{ CI: 43.6–72.1})\) crizotinib and 19.0% \((95\% \text{ CI: 9.7–30.7})\) alectinib in patients with measurable/non-measurable baseline CNS metastases \(\text{(supplementary Table S7, available at Annals of Oncology online)}\). The CIR of non-CNS progression and death in these patients are shown in supplementary Figure S2, available at Annals of Oncology online.

### Discussion

Based on the ALEX data, the National Comprehensive Cancer Network guidelines were updated to include alectinib as a category 1 recommendation for first-line treatment of ALK⁺ NSCLC [15]. Our data confirm that alectinib demonstrates superior efficacy versus crizotinib in treatment-naive advanced ALK⁺ NSCLC, regardless of baseline CNS disease or prior radiotherapy.

Baseline CNS metastases are an adverse prognostic factor in ALK⁺ advanced NSCLC [16]. Although PROFILE 1014 established crizotinib as the SOC first-line therapy for ALK⁺ NSCLC [2], only patients with treated and stable CNS disease were enrolled, and, in contrast to ALEX, regular CNS imaging was only conducted in patients with known baseline CNS disease [4, 7]. In ASCEND-4 (phase III; first-line ceritinib versus chemotherapy), 32% of patients had asymptomatic or neurologically stable...
baseline CNS disease [17]. PFS was longer with ceritinib versus chemotherapy in patients without baseline CNS metastases [HR 0.48 (95% CI: 0.33–0.69), median PFS 26.3 versus 8.3 months] [17]. Although CNS responses are well documented with ceritinib, these differences, together with the median PFS of ceritinib in those with baseline CNS metastases (10.7 months), raise concerns about the durability of the CNS efficacy of ceritinib. Indeed, the CNS is a common site of progression in patients treated with crizotinib or ceritinib [17, 18].

ALEX is the first ALK-inhibitor study to include prospective, standardized assessment of CNS lesions in the ITT population, regardless of baseline CNS disease, allowing the potential CNS protective effect of the drug to be assessed. Alectinib significantly prolonged PFS in patients with/without baseline CNS disease versus crizotinib, and significantly improved intracranial ORR versus crizotinib, irrespective of radiotherapy history.

Our data are in agreement with a pooled analysis of alectinib phase II trials, which demonstrated that CNS efficacy of alectinib is maintained regardless of radiotherapy history in crizotinib-pretreated patients [12]. ALEX CNS progression data are consistent with findings from the phase III J-ALEX trial, in which first-line alectinib reduced the risk of CNS progression versus crizotinib [19]. However, CNS metastases were not stratified in J-ALEX. CNS DoR was longer with alectinib versus crizotinib in all ALEX subgroups. As ALEX only permitted patients with asymptomatic CNS disease, we do not yet know the potential of alectinib in improving CNS outcomes in symptomatic patients versus local CNS therapies. The ALEX data strongly suggest that in asymptomatic patients, treating CNS metastases with alectinib alone may result in a reduced or delayed need for local CNS treatment. Alectinib significantly reduced the risk of CNS progression versus crizotinib irrespective of the subgroup analyzed, suggesting...
Table 2. Risk of central nervous system (CNS) progression, non-CNS progression, and death [Independent review committee (IRC) Response Evaluation Criteria in Solid Tumors (RECIST) v1.1] in patients with/without baseline CNS metastases

<table>
<thead>
<tr>
<th>Patients with baseline CNS metastases</th>
<th>Crizotinib (n = 58)</th>
<th>Alectinib (n = 64)</th>
<th>Cause-specific HR (95% CI)</th>
<th>P value (log-rank)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS progression without prior non-CNS PD</td>
<td>33 (56.9)</td>
<td>12 (18.8)</td>
<td>0.18 (0.09–0.36)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Non-CNS progression without prior CNS PD</td>
<td>14 (24.1)</td>
<td>11 (17.2)</td>
<td>0.35 (0.15–0.84)</td>
<td>0.0154</td>
</tr>
<tr>
<td>Death without prior CNS or non-CNS PD</td>
<td>4 (6.9)</td>
<td>7 (10.9)</td>
<td>0.66 (0.17–2.55)</td>
<td>0.55</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients without baseline CNS metastases</th>
<th>Crizotinib (n = 93)</th>
<th>Alectinib (n = 88)</th>
<th>Cause-specific HR (95% CI)</th>
<th>P value (log-rank)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS progression without prior non-CNS PD</td>
<td>35 (37.6)</td>
<td>6 (6.8)</td>
<td>0.14 (0.06–0.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Non-CNS progression without prior CNS PD</td>
<td>19 (20.4)</td>
<td>25 (28.4)</td>
<td>1.16 (0.64–2.11)</td>
<td>0.63</td>
</tr>
<tr>
<td>Death without prior CNS or non-CNS PD</td>
<td>5 (5.4)</td>
<td>4 (4.5)</td>
<td>0.71 (0.19–2.65)</td>
<td>0.60</td>
</tr>
</tbody>
</table>

For each patient, the first event of CNS progression, systemic progression, or death was counted. Therefore, patients who had CNS progression first were no longer at risk for a systemic progression or death in this analysis. Patients with CNS progression who also had systemic progression were included in the CNS progression group. Hazard ratios (HRs) and 95% confidence interval (CI) were estimated by Cox regression where patients with competing events were censored at the time of these events. P values are from two-sided cause-specific log-rank tests. PD, disease progression.

Figure 3. Cumulative incidence rate (CIR) of central nervous system (CNS) progression. For each patient, the first event of CNS or non-CNS progression or death was counted: (A) patients with CNS metastases at baseline, (B) patients without CNS metastases at baseline, (C) patients with CNS metastases at baseline who had received prior radiotherapy, and (D) patients with CNS metastases at baseline who had not received prior radiotherapy. CI, confidence interval.
that alectinib may have protective effect against development of CNS metastases. When interpreting the CIR of non-CNS progression and death, we must consider the methodology used. Once a patient develops CNS progression, CIR analysis does not analyze whether subsequent systemic progression occurred earlier with alectinib or crizotinib. As such, some patients were documented as having CNS progression but may also have experienced non-CNS progression.

Pooled analysis of phase II studies demonstrated that alectinib is active against treated/untreated CNS metastases in ALK+ NSCLC, regardless of assessment criteria (RECIST v1.1 versus RANO-BM, http://recist.eortc.org/wp-content/uploads/2015/03/RECISTGuidelines.pdf) [20]. Trends we observed are consistent with the pooled phase II data, and the ALEX ITT data [13]. Although some subgroups contained small patient numbers, our findings are consistent with those reported previously [12, 19].

Figure 4. Central nervous system (CNS) response: (A) patients with measurable CNS disease at baseline who had received prior radiotherapy, (B) patients with measurable CNS disease at baseline who had not received prior radiotherapy, (C) patients with measurable or non-measurable CNS disease at baseline who had received prior radiotherapy, and (D) patients with measurable or non-measurable CNS disease at baseline who had not received prior radiotherapy. CI, confidence interval; CR, complete response; DoR, duration of response; NR, not reached; RT, radiotherapy.
The key strength of our analysis comes from prospective assessment of CNS secondary lesions in the ITT population. CNS results from ALEX consolidate alectinib as the SOC for untreated, advanced ALK+ NSCLC irrespective of presence/absence of baseline CNS metastases.

Acknowledgements

The authors would like to thank the patients, their families, and the participating study centres. The authors would also like to thank Emmanuel Mitry for his valuable contribution to the study. Third-party medical writing assistance, under the direction of the authors, was provided by Emma Evans, PhD, of Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd (no grant number applies).

Disclosure

SG has received honoraria/consultancy fees from Ariad, AstraZeneca, Bristol-Myers Squibb (BMS), Pfizer, and Roche/Genentech; SP has received education grants, provided consultation, attended advisory boards and/or provided lectures for Amgen, AstraZeneca, Boehringer-Ingelheim (BI), BMS, Clovis Oncology, Eli Lilly, F. Hoffmann-La Roche Ltd, Guardant health, Janssen, Merck Serono, Merck Sharp & Dohme (MSD), Merrimack, Morphotek, Pfizer, Regeneron, and Takeda; TM has been compensated for a leadership role with Sanonics Ltd, received honoraria/consulting fees from ACEA Biosciences, AstraZeneca, BI, BMS, Celgene, Chimerix, Cirina, Fishawack Facilitate, Ignitya, Janssen, Lilly, Merck Serono, MSD, Novartis, OncoGenex, Pfizer, Roche/Genentech, SFJ Pharmaceutical, Takeda, and Vertex and received research funding from AstraZeneca, BMS, Clovis Oncology, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceutical, and XCovery; ATS has received honoraria and research funding from Novartis, Pfizer, and Roche/Genentech and acted in a consulting/advisory role to ARIAD, Blueprint Medicines, Ignitya, KSQ Therapeutics, Loxo, Natera, Novartis, Pfizer, and Roche/Genentech; DWK has received non-financial support from F. Hoffmann-La Roche Ltd for travel to advisory meetings; SIO has received honoraria/consultancy fees from Ariad, AstraZeneca, Pfizer, Roche/Genentech, and TP Therapeutics, participated in speakers’ bureaus for ARIAD, AstraZeneca, and Roche/Genentech, received research funding from ARIAD, AstraZeneca, Daiichi Sankyo, Pfizer, and Roche/Genentech, and owns stocks in TP Therapeutics; MP has received honoraria from Amgen, AstraZeneca, BI, BMS, Clovis Oncology, Eli Lilly, Merck, Novartis, Pierre Fabre, Pfizer, and Roche/Genentech; AW has received travel, accommodation, or expenses from, and participated in speakers’ bureaus for, BMS and Pfizer; SN has participated in speakers’ bureaus for AstraZeneca, BI, BMS, Eli Lilly, Incyte, MSD, and Roche; AZ was an employee of F. Hoffmann-La Roche Ltd at the time of study conduct and owns Roche stocks; TL is an employee of F. Hoffmann-La Roche Ltd, has received travel, accommodation, or expenses from Roche and owns Roche stocks; EN is an employee of F. Hoffmann-La Roche Ltd and owns Roche stocks; BB is an employee of F. Hoffmann-La Roche Ltd and owns Roche stocks; DRC has received honoraria or consulting fees from AbbVie, Ariad, Array, Celgene, Clovis Oncology, Eli Lilly, Genoptix, G1 Therapeutics, Novartis, Onconova, and Roche/Genentech. All remaining authors have declared no conflicts of interest.

Data sharing

Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche’s criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

References

14. Camidge DR, Peters S, Mok T et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (AL) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. JCO 2018; 36(Suppl 15): 9043. abstract